Company Overview and News

 
KLCI slips below 1,800 level as sellers outpace buyers

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI slipped back to below the 1,800-point level at midday break today, as sellers overtook buyers at the local bourse.
HLFBF 7113 7158 BATS TPGVF 4162 2089 5199 5347 7668 TNABY AXXTF 2836 HIPEF 1929 UPBMF 1082 6399 1163 5202 8311 2593 TGLVY 5139 0900 6888 TNABF 3719

 
Hai-O 1Q net profit down 38.5% on lower MLM and retail revenue

2018-09-27 theedgemarkets
KUALA LUMPUR: Hai-O Enterprise Bhd registered a reduced net profit of RM11 million for the first financial quarter ended July 31, 2018 (1QFY19), 38.5% lower than RM17.87 million a year ago, owing to lower multilevel marketing (MLM) and retail revenue.
7668

 
KLCI erases earlier loss, crosses 1,800-level

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI erased its earlier losses and rose at mid-morning to cross the 1,800-point level.
5072 8621 7158 BATS 4162 7215 2089 5199 5347 3301 7668 TNABY AXXTF HIPEF PNAGF UPBMF 1163 5202 8311 6033 2593 5139 PNADF 0900 6888 TNABF 3719

 
KLCI seen trending sideways, immediate support at 1,786

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI is expected to trend sideways today with immediate support at 1,786.
5080 BRDBF 5088 6399 5014 7088 2593 5210 3204 7668 6888 MYPRY AXXTF

 
George Kent, Axiata, Astro, Bumi Armada, United Malacca, Poh Huat, MAHB, Apex Equity, Poh Kong, Hai-O and Eversendai

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): Based on corporate announcements and news flow today, companies in focus on Thursday (Sept 27) may include: George Kent (Malaysia) Bhd, Axiata Group Bhd, Astro Malaysia Holdings Bhd, Bumi Armada Bhd, United Malacca Bhd, Poh Huat Resources Holdings Bhd, Malaysia Airports Holdings Bhd (MAHB), Apex Equity Holdings Bhd, Poh Kong Holdings Bhd, Hai-O Enterprise Bhd and Eversendai Corp Bhd
5080 BRDBF 5088 6399 5014 7088 2593 5210 3204 7668 6888 MYPRY AXXTF

 
Hai-O 1Q net profit down 38.5% on lower MLM, retail revenue

2018-09-26 theedgemarkets
KUALA LUMPUR(Sept 26): Hai-O Enterprise Bhd registered a reduced net profit of RM11 million for the first financial quarter ended July 31, 2018 (1QFY19), 38.5% lower than RM17.87 million a year ago, owing to lower multi-level marketing (MLM) and retail revenue.
7668

 
KLCI seen extending consolidation, firm crude oil price to offer respite

2018-09-26 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI is expected to continue its consolidation phase and hover below the 1,800-point level but may find some respite from high crude oil prices.
1201 5016 6556 7668 5219 4405 6874 2143 5189

 
KLCI seen extending consolidation, firm crude oil to offer respite

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 26): The FBM KLCI is expected to continue its consolidation phase and hover below the 1,800-point level but may find some respite from high crude oil prices.
1201 5016 6556 7668 5219 4405 6874 2143 5189

 
Sapura Energy, ECM Libra, Hai-O, Velesto, Maxwell, Deleum, Pestech, OpenSys, Sumatec, KUB, V.S. Industry, Ann Joo, Maybulk, Tan Chong Motor and Warisan TC Holdings

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): Based on corporate announcements and news flow today, companies in focus on Wednesday (Sept 26) may include: Sapura Energy Bhd, ECM Libra Financial Group Bhd, Hai-O Enterprise Bhd, Velesto Energy Bhd, Maxwell International Holdings Bhd, Deleum Bhd, Pestech International Bhd, OpenSys (M) Bhd, Sumatec Resources Bhd, KUB Malaysia Bhd, V.S. Industry Bhd, Ann Joo Resources Bhd, Malayan Bulk Carriers Bhd (Maybulk), Tan Chong Motor Holdings Bhd and Warisan TC Holdings Bhd
PBLOF 6874 1295 2143 5189 1201 5016 6556 7668 5219 4405 BSMAF 1818

 
Hai-O sees challenging year ahead

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): Hai-O Enterprise Bhd sees a challenging year ahead for the company, due to uncertainties of new policies from the new government, as well as the US-China trade war.
7668

 
KLCI drifts lower, tracks regional markets

2018-09-25 theedgemarkets
KUALA LUMPUR (Sept 25): The FBM KLCI drifted lower at mid-morning, tracking the lacklustre regional markets.
HLFBF APEXF BRDBF 7090 7181 7036 1082 5681 BATS 4162 1163 5256 5199 5210 4456 3301 0026 7668 HIPEF 3719

 
KLCI stages mild rebound, gains seen capped

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): The FBM KLCI staged a mild rebound in early trade this morning, lifted by select blue chips but any gain is seen capped.
HLFBF 5797 7668 6645 0090 4405 1082 5681 3034

 
KLCI struggles to recoup losses, stages marginal recovery

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): The FBM KLCI struggled to recoup some lost ground in the morning session today amid some choppy trading.
7047 BATS 4162 5246 5202 9334 6033 7233 2852 5029 PNADF 5347 5225 7668 6645 TNABY TNABF Q0F IHHHF PNAGF

 
Hai-O’s MLM distributor force seen to grow to 160,000 by end-FY19

2018-08-10 theedgemarkets
Hai-O Enterprise Bhd (Aug 9, RM4.34) Maintain buy with a lower target price (TP) of RM5.39: After a recent meeting with management, we make adjustments to our distributorship growth forecast as we see a tapering off of that growth but foresee potentially higher revenue per distributor, which will likely be further spurred by the introduction of new fashion and lifestyle products. While we expect the slowdown seen in the fourth quarter ended April 2018 (4QFY18) to linger into 1QFY19, we believe sales will pick up in the subsequent quarters.
7668

 
KLCI pares gains, struggles to breach 1,800 level

2018-08-08 theedgemarkets
KUALA LUMPUR (Aug 8): The FBM KLCI pared some of its gains at mid-morning today, struggling to breach the 1,800-point level.
PBLOF BATS 4162 7087 7043 1295 5168 5014 5007 KLKBY 5029 2445 2542 5225 3867 5517 7668 2739 MYPRY 2836 Q0F IHHHF HRGHY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...